» Articles » PMID: 35300098

Cannabis Use Among Patients with Alopecia Areata: A Cross-Sectional Survey Study

Overview
Date 2022 Mar 18
PMID 35300098
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Little is known about cannabis use among patients with alopecia areata (AA). These patients often experience significant psychosocial burden and may seek alternative therapies beyond that of traditional medical treatments, such as cannabis.

Objective: To characterize cannabis use among patients with AA.

Design: This was a cross-sectional study conducted from March 9, 2021, to March 22, 2021, using a web-based survey distributed to adult patients with AA using the National AA Foundation's email listserv and social media platforms.

Results: 1,087 participants completed the survey (completion rate: 88.1%). Most participants were female ( = 870, 83.3%) and Caucasian ( = 771, 73.8%), with a mean age of 47.6 ± 15.5 years. 65.9% ( = 689) of participants with AA had a history of cannabis use and among those, 51.8% ( = 357) were current cannabis users. The most common reason for cannabis use among current users was for AA-related symptoms ( = 199, 55.7%), with the greatest perceived improvement in symptoms of stress ( = 261, 73.1%) and anxiety, sadness, and depression ( = 234, 65.6%). 80.4% ( = 287) indicated that cannabis had no impact on their hair loss.

Conclusion: Cannabis use is common among patients with AA and is often used to alleviate the psychosocial symptoms related to AA, despite the lack of perceived improvement in hair regrowth.

Citing Articles

Comprehensive Insight into Cutaneous Application of Hemp.

Zugic A, Martinovic M, Tadic V, Rajkovic M, Racic G, Nesic I Pharmaceutics. 2024; 16(6).

PMID: 38931870 PMC: 11207338. DOI: 10.3390/pharmaceutics16060748.


Reduced rates of substance use disorder in patients with alopecia: An all of us case-control study.

Konisky H, Chen P, Kobets K Arch Dermatol Res. 2024; 316(6):324.

PMID: 38822896 DOI: 10.1007/s00403-024-03047-4.


Perceptions and engagement of patients with chronic conditions on the use of medical cannabis: a scoping review.

Pomey M, Jutras-Aswad D, Paquette J, Saadi K, Taguemout M, Ikene D Eur J Med Res. 2024; 29(1):211.

PMID: 38561859 PMC: 10983766. DOI: 10.1186/s40001-024-01803-w.


Physician values in alopecia areata treatment decision-making: A qualitative assessment.

Han J, Manjaly P, Lee K, Kassamali B, Kus K, Perez-Chada L JAAD Int. 2023; 11:14-23.

PMID: 36818678 PMC: 9932109. DOI: 10.1016/j.jdin.2022.11.010.

References
1.
Kosiba J, Maisto S, Ditre J . Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Soc Sci Med. 2019; 233:181-192. DOI: 10.1016/j.socscimed.2019.06.005. View

2.
Hussain S, Mostaghimi A, Barr P, Brown J, Joyce C, Huang K . Utilization of Mental Health Resources and Complementary and Alternative Therapies for Alopecia Areata: A U.S. Survey. Int J Trichology. 2017; 9(4):160-164. PMC: 5655624. DOI: 10.4103/ijt.ijt_53_17. View

3.
Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J . Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study. J Investig Dermatol Symp Proc. 2020; 20(1):S62-S68. DOI: 10.1016/j.jisp.2020.05.007. View

4.
Mostaghimi A, Napatalung L, Sikirica V, Winnette R, Xenakis J, Zwillich S . Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review. Dermatol Ther (Heidelb). 2021; 11(3):867-883. PMC: 8163950. DOI: 10.1007/s13555-021-00512-0. View

5.
Rodgers A . Why Finding a Treatment for Alopecia Areata Is Important: A Multifaceted Perspective. J Investig Dermatol Symp Proc. 2017; 19(1):S51-S53. DOI: 10.1016/j.jisp.2017.10.008. View